Skip to content

Press Release · Press Releases

Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026

Issued by PR Newswire

Image: PR Newswire

LEXINGTON, Mass., Nov. 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its third quarter 2026...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories

Press Release

Faith Leaders Urge SCC to Reject Dominion-NextEra Merger

Interfaith gathering calls on Virginia regulators to protect ratepayers RICHMOND, Va., Nov. 5, 2026 /PRNewswire/ -- Faith leaders and community advocates gathered outside the Virginia State Corporation Commission (SCC) today to oppose NextEra Energy's proposed $67 billion acquisition of...

PR Newswire ·